Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afuresertib in hematologic malignancies
NCT00881946Phase 2Completed
- Sponsor
- Accenture
- Start
- Jul 2009
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of afuresertib in chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), multiple myeloma (MM) and 2 more, sponsored by Accenture. Primary endpoints: Physical examination, Electrocardiogram and 10 more. Started Jul 2009; status: completed.
02
Drugs
afuresertib
03
Conditions
chronic lymphocytic leukemia (CLL)chronic myelogenous leukemia (CML)multiple myeloma (MM)non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00881946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00881946.